Ebos Group Limited Ordinary Shares

EBO.NZX

Health Care

Formerly Early Bros Dental & Surgical Supplies Ltd, the company's business was restructured in the 1990s. The major focus now is the marketing of medical consumable products, and growth has been assisted by acquisitions on both sides of the Tasman since 1996. These included Richard Thomson & Co, Health Support Ltd, Maygar Medical, Medic Corporation, Nature's Kiss creams and the Australian Allersearch range of asthma products. In October 2002 it announced a joint venture of its former Medic Scientific division with Global Science, giving EBO 47.5% of the new entity. In 2004, the company acquired healthcare product distributor Vernon-Carus and the Melbourne based company, Stelmara Medical. In January 2005 it increased its stake in Global Science from 47.5% to 67% and in March that year acquired the Australian business of Quantum Scientific. In December 2005 it raised its shareholding in Global Science to 100%. Global Science also acquired 100% of Scientific Supplies Ltd - a NZ-based specialty supplier of chemicals to the scientific market. In August 2007, it acquired pharmaceuticals distributor PRNZ for $86.3m in cash and shares. In July 2008 it acquired MedBio Scientific. In April 2009, EBO entered into a new issuance and share buyback as part of its profit distribution plan. Under the Profit Distribution Plan shareholders can elect to have the company buy back shares issued to them under the Plan at the issue price of $4.691798 per share. As a result of shareholder elections the company achieved an off-market buy back of 279,875 shares. Of the total number of bonus shares issued in respect of the 2009 interim profit distribution (of 10.5 cps), 74.1% of shares are being retained with 25.9% electing the buyback option. The company has elected to cancel all of the 279,875 shares bought back. With the issue of 1,080,305 new shares and the cancellation of 279,875 shares bought back, the total number of shares on issue is now 48,980,799. On 14 June 2013, shareholders elected to proceed with a pro-rata renounceable Entitlement Offer of 7 new ordinary shares for every 20 existing ordinary shares held on the Record Date. The transaction settlement is expected to take place on or about 5 July 2013. In November 2015, the company acquired Red Seal, a leading New Zealand natural health product business, for NZ$80 million.

Market Data

Price

$19.520

+0.0%
Market Cap

$4.0B

P/E Ratio

14.8x

EPS

$1.318

Div. Yield

6.66%

52-Week Change

-0.5%

Recent Announcements

18 May 2026 Neutral

Capital Change Notice - Employee Share Plan

EBOS Group Limited issued 9,992 ordinary shares at NZ$21.57 per share to participants in its Employee Share Plan on 18 May 2026, representing 0.0048% of the total issued shares, bringing total shares outstanding to 206,939,594.

18 May 2026 Neutral

Performance Rights Update

EBOS Group Limited announces that 4,468 performance rights have lapsed, reducing the total performance rights on issue to 1,424,949 as of 18 May 2026.

6 May 2026 Neutral

Performance Rights Update

EBOS Group Limited announced that 5,116 performance rights lapsed on 1 May 2026 due to unmet conditions, leaving 1,429,417 performance rights on issue.

1 May 2026 Neutral

Performance Rights Update

EBOS Group Limited reports that 703 performance rights have lapsed due to unmet or unsatisfiable conditions, reducing total performance rights on issue to 1,434,533.

30 Apr 2026 Supplementary Neutral

Investor Day Presentation

EBOS Group Limited held an Investor Day in Sydney on 30 April 2026, presenting group strategy, financial framework, and divisional updates across its four operating divisions: Symbion & Healthcare Distribution, Retail Pharmacy Brands, Medical Technology, and Animal Care.

28 Apr 2026 Date Announcement Neutral

Advance Notice - Investor Day

EBOS Group Limited will host an investor day on Thursday, 30 April 2026, with a live webcast commencing at 10.45am NZDT / 8.45am AEST, with presentation materials to be made available through NZX, ASX, and the company's investor website.

28 Apr 2026 Neutral

Performance Rights Update

EBOS Group Limited reports that 7,878 performance rights have lapsed due to unmet conditions, reducing total performance rights on issue from 1,443,114 to 1,435,236.

22 Apr 2026 Guidance Negative

Impact of elevated fuel costs on FY26 earnings outlook

EBOS Group Limited has lowered its FY26 underlying EBITDA guidance to $610–$620 million from $615–$635 million due to elevated fuel and energy costs that have exceeded previous assumptions, resulting in an estimated $5–10 million impact that cannot be fully passed through to customers due to service continuity requirements and government arrangements. The company is implementing efficiency measures and engaging with stakeholders on cost recovery, though timing and outcomes remain uncertain.

17 Apr 2026 Neutral

Capital Change Notice - Employee Share Plan

EBOS Group Limited issued 5,553 fully paid ordinary shares to employees under its Employee Share Plan at NZ$23.04 per share on 17 April 2026, representing 0.0027% of total issued capital, bringing total ordinary shares on issue to 206,929,602.

2 Apr 2026 Insider Neutral

Ongoing Disclosure Notices

Three EBOS Group Limited directors—Stuart McLauchlan, Julie Tay, and Coline McConville—each acquired ordinary shares on 27 March 2026 through dividend reinvestment plans, with McLauchlan acquiring 134 shares (NZ$2,960.06), Tay acquiring 71 shares (NZ$1,568.14), and McConville acquiring 22 shares (NZ$485.98).

Get real-time alerts for EBO

Receive AI-powered earnings summaries and instant notifications when Ebos Group Limited Ordinary Shares releases results.

Register Free